Skip to main content

Advertisement

SpringerLink
Log in

Leptin: Linking obesity, the metabolic syndrome, and cardiovascular disease

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

The incidence and prevalence of obesity and the metabolic syndrome have risen markedly in the past decade, representing a serious cardiovascular health hazard with significant morbidity and mortality. The etiology of the metabolic syndrome and its various pathogenic mechanisms are incompletely defined and under intense investigation. Contemporary research suggests that the adipocyte-derived hormone leptin may be an important factor linking obesity, the metabolic syndrome, and cardiovascular disorders. Although recent evidence indicates that under normal conditions leptin may be an important factor in regulating pressure and volume, during situations of chronic hyperleptinemia and leptin resistance, this hormone may function pathophysiologically for the development of hypertension and cardiac and renal diseases. Future research will determine if reduction of circulating leptin and/or blockade of its peripheral actions can confer cardiovascular and renal protection in hyperleptinemic patients with obesity and the metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ogden CL, Carroll MD, Curtin LR, et al.: Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006, 295:1549–1555.

    Article  PubMed  CAS  Google Scholar 

  2. Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesity associated cardiovascular and renal disease. Am J Sci 2002, 324:127–137.

    Article  Google Scholar 

  3. Grundy SM, Brewer HB Jr, Cleeman JI, et al.: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433–438.

    Article  PubMed  Google Scholar 

  4. Unger RH: Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 2003, 14:398–403.

    Article  PubMed  CAS  Google Scholar 

  5. Unger RH: Hyperleptinemia: protecting the heart from lipid overload. Hypertension 2005, 45:1031–1034.

    Article  PubMed  CAS  Google Scholar 

  6. Franks PW, Brage S, Luan J, et al.: Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005, 13:1476–1484.

    PubMed  CAS  Google Scholar 

  7. Patel S, Villarreal D, Mukherjee R, et al.: Renal and vascular actions of leptin: Emerging concepts in obesity and hypertension. Adipocytes 2007, 2:101–108.

    Google Scholar 

  8. Banks AS, Davis SM, Bates SH, et al.: Activation of downstream signals by the long form of the leptin receptor. J Biol Chem 2000, 275:14563–14572.

    Article  PubMed  CAS  Google Scholar 

  9. Munzberg H, Myers MG Jr: Molecular and anatomical determinants of central leptin resistance. Nature 2005, 8:566–570.

    Google Scholar 

  10. Hoggard N, Mercer JG, Rayner DV: Localization of leptin receptor mRNA splice variants in murine peripheral tissues by RT-PCR and in situ hybridization. Biochem Biophys Res Commun 1997, 232:383–387.

    Article  PubMed  CAS  Google Scholar 

  11. Haynes WG, Morgan DA, Walsh SA, et al.: Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997, 100:270–278.

    Article  PubMed  CAS  Google Scholar 

  12. Dunbar JC, Hu Y, Lu H: Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997, 40:2043.

    Google Scholar 

  13. Guha PK, Villarreal D, Reams GP, et al.: Role of leptin in the regulation of body fluid volume and pressures. Am J Ther 2003, 10:211–218.

    Article  PubMed  Google Scholar 

  14. Villarreal D, Reams GP, Freeman RH, et al.: Renal effects of leptin in normotensive, hypertensive and obese rats. Am J Physiol 1998, 275:R2056–R2060.

    PubMed  CAS  Google Scholar 

  15. Jackson EK, Li P: Human leptin has natriuretic activity in the rat. Am J Physiol 1997, 272:F333–F338.

    PubMed  CAS  Google Scholar 

  16. Lembo L, Vecchione C, Fratta L: Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000, 49:293–297.

    Article  PubMed  CAS  Google Scholar 

  17. Vecchione C, Maffei A, Colella S, et al.: Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002, 51:168–173.

    Article  PubMed  CAS  Google Scholar 

  18. Fruhbeck G: Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999, 48:903–908.

    Article  PubMed  CAS  Google Scholar 

  19. Mitchell JL, Morgan DA, Correia ML, et al.: Does leptin stimulate nitric oxide to oppose the effects of sympathetic activation? Hypertension 2001, 38:1081–1086.

    Article  PubMed  CAS  Google Scholar 

  20. Gardiner SM, Kemp PA, March JE, et al.: Regional hemodynamic effects of recombinant murine or human leptin in conscious rats. Br J Pharmacol 2000, 130:805–810.

    Article  PubMed  CAS  Google Scholar 

  21. Quehenberger P, Exner M, Sunder-Plassmann R, et al.: Leptin induces endothelin-1 endothelial cells in vitro. Circ Res 2002, 90:711–718.

    Article  PubMed  CAS  Google Scholar 

  22. Bouloumine A, Marumo T, Lofanton M, et al.: Leptin induces oxidative stress in human endothelial cells. FASEB J 1999, 13:1231–1238.

    Google Scholar 

  23. Beltowski J: Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006, 24:789–801.

    Article  PubMed  CAS  Google Scholar 

  24. Correia MI, Haynes WG, Rahmouni K: The concept of selective leptin resistance: Evidence from agouti yellow obese mice. Diabetes 2002, 51:439–442.

    Article  PubMed  CAS  Google Scholar 

  25. Rahmouni K, Correia LG, Haynes WG, et al.: Obesity-associated hypertension, new insights into mechanisms. Hypertension 2005, 45:9–14.

    Article  PubMed  CAS  Google Scholar 

  26. Tune JD, Consodine R: Effects of leptin on cardiovascular physiology. J Am Soc Hypertens 2007, 14:231–241.

    Article  Google Scholar 

  27. Shek EW, Brands MW, Hall JE: Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31:409–414.

    PubMed  CAS  Google Scholar 

  28. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al.: Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000, 105:1243–1252.

    Article  PubMed  CAS  Google Scholar 

  29. Agata J, Masuda A, Takada M, et al.: High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 1997, 10:1171–1174.

    Article  PubMed  CAS  Google Scholar 

  30. Kazumi T, Kawaguchi A, Katoh J, et al.: Fasting insulin and leptin serum levels are associated with systolic blood pressure independent of percentage body fat and body mass index. J Hypertens 1999, 17:1451–1455.

    Article  PubMed  CAS  Google Scholar 

  31. Makris TK, Stavroulakis GA, Krespi PG, et al.: Elevated plasma immunoreactive leptin levels preexist in healthy offspring of patients with essential hypertension. Am Heart J 1999, 138:922–925.

    Article  PubMed  CAS  Google Scholar 

  32. Serradeil-Le G, Raufaste D, Brossard G, et al.: Characterization and localization of leptin receptors in the rat kidney. FEBS Lett 1997, 404:185–191.

    Article  Google Scholar 

  33. Bado A, Levasseur S, Attoub S: The stomach is a source of leptin. Nature 1998, 394:790–793.

    Article  PubMed  CAS  Google Scholar 

  34. Villarreal D, Reams GP, Freeman RH: Effects of renal denervaton on the sodium excretory action of leptin in hypertensive rats. Kidney Int 2000, 58:989–994.

    Article  PubMed  CAS  Google Scholar 

  35. Beltowski J, Wojcicka G: Human leptin administered intraperitoneally stimulates natriuresis and decreases renal medullary Na+, K+-ATPase activity in the rat-impaired effect in dietary-induced obesity. Med Sci Monit 2002, 8: BR221–BR229.

    PubMed  CAS  Google Scholar 

  36. Villarreal D, Reams GP, Samar H, et al.: Effects of chronic nitric oxide inhibition on the renal excretory response to leptin. Obes Res 2004, 12:1006–1010.

    PubMed  CAS  Google Scholar 

  37. Ortiz PA, Garvin JL: Role of nitric oxide in the regulation of nephron transport. Am J Physiol 2002, 282:F777–F784.

    CAS  Google Scholar 

  38. Villarreal D, Reams GP, Samar H: Leptin blockade attenuates sodium excretion in saline-loaded normotensive rats. Mol Cell Biochem 2006, 283:153–157.

    Article  PubMed  CAS  Google Scholar 

  39. Dobrian AD, Schriver SD, Lynch T, et al.: Effect of salt on hypertension and oxidative stress in rat model on diet-induced obesity. Am J Physiol 2003, 285:F619–F628.

    CAS  Google Scholar 

  40. Konstantinides S, Schafer K, Koschnick S, et al.: Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001, 108:1533–1540.

    PubMed  CAS  Google Scholar 

  41. Sierra-Honigmann MR, Nath AK, Murakami C.: Biological action of leptin as an angiogenic factor. Science 1998, 281:1683–1686.

    Article  PubMed  CAS  Google Scholar 

  42. Umemoto Y, Tsuji K, Yang FC, et al.: Leptin stimulates the proliferation of murine myelocytic and primitive haematopoietic progenitor cells. Blood 1997, 90:3438–3443.

    PubMed  CAS  Google Scholar 

  43. Paolisso G, Tangliamonte MR, Galderisi M, et al.: Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin resistant men. Hypertension 1999, 34:1047–1052.

    PubMed  CAS  Google Scholar 

  44. Luo J, Zhang G, Chen M: Leptin and cardiovascular diseases. Drug News Perspect 2005, 18:427–431.

    Article  PubMed  CAS  Google Scholar 

  45. Karmazyn M, Purdham DM, Rajapurohitam V: Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc Med 2007, 17:206–211.

    Article  PubMed  CAS  Google Scholar 

  46. Rajapurohitam V, Gan XT, Kirshenbaum LA, et al.: The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003, 93:277–279.

    Article  PubMed  CAS  Google Scholar 

  47. Barouch LA, Berkowitz DE, Harrison RW, et al.: Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003, 108:754–759.

    Article  PubMed  CAS  Google Scholar 

  48. Tajmir P, Ceddia RB, Li RK: Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase and phosphatidylinositol 3-kinase-dependent signaling pathways. Endocrinology 2004, 145:1550–1555.

    Article  PubMed  CAS  Google Scholar 

  49. Atkinson LL, Fischer MA, Lopaschuk GD: Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 2002, 277:29424–29430.

    Article  PubMed  CAS  Google Scholar 

  50. Nickola M, Wold L, Colligan P, et al.: Leptin attenuates cardiac contraction in rat ventricular myocytes: role of NO. Hypertension 2000, 36:501–505.

    PubMed  CAS  Google Scholar 

  51. Wold LE, Relling DP, Duan J, et al.: Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of JAK/STAT pathway. Hypertension 2002, 39:69–74.

    Article  PubMed  CAS  Google Scholar 

  52. Tritos NA, Manning WJ, Danias PG, et al.: Role of leptin in the development of cardiac hypertrophy in experimental animals and humans. Circulation 2004, 109:e67.

    Article  PubMed  Google Scholar 

  53. Schulze PC, Kratzsch J, Linke A, et al.: Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 2003, 5:33–40.

    Article  PubMed  Google Scholar 

  54. Sharma V, McNeill J: The emerging roles of leptin and ghrelin in cardiovascular physiology and pathophysiology. Curr Vasc Pharmacol, 2005, 3:169–180.

    Article  PubMed  CAS  Google Scholar 

  55. Wallace M, McMahon AD, Packard CJ, et al.: Plasma leptin and the risk of cardiovascular disease in the West Of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001, 104:3052–3056.

    Article  PubMed  CAS  Google Scholar 

  56. Couillard C, Lamarche B, Mauriège P, et al.: Leptinemia is not a risk factor for ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Diabetes Care 1998, 21:782–786.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Cardiology, SUNY Upstate Medical University, Room 6142, 750 East Adams Street, Syracuse, NY, 13210, USA

    Daniel Villarreal

Authors
  1. Sanjeev B. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Garry P. Reams
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert M. Spear
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ronald H. Freeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Daniel Villarreal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Villarreal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patel, S.B., Reams, G.P., Spear, R.M. et al. Leptin: Linking obesity, the metabolic syndrome, and cardiovascular disease. Current Science Inc 10, 131–137 (2008). https://doi.org/10.1007/s11906-008-0025-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-008-0025-y

Keywords

Search

Navigation